According to a new study, before suggesting the prostate cancer patients to have a persistent biopsy treatment, a new DNA-based biomarker blood test that balances the current prostate-specific antigen (PSA) test could significantly improve the detection.
This new technique came into limelight when the University of Cincinnati (UC) researchers carried out the existing meta-analysis data related to DNA methylation, related to the body fluids that increase cancer risks.
Talking about the study, researchers accounted that before conducting this study, the evaluation of the specific cancer biomarker entitled as GSTP1 was their main aim, as they always believed that this tool would decline the risk of this deadly cancer and many people would live a healthy life.
"The PSA test is highly sensitive, but it cannot differentiate between prostate cancer and benign prostatic conditions such as benign prostatic hyperplasia, leading many men to have unnecessary biopsies”, said Tianying Wu, the lead author of the study and the Assistant Professor of environmental health at the University of Cincinnati. "Measuring GSTPI in plasma or urine is an easy and non-invasive test. This biomarker will give physicians reassurance regards to whether to conduct biopsies in selected patients”.
Good News USA
- Vodafone NZ’s new ‘Red Home’ packages will offer UFB and 150 TV channels
- Vodafone NZ’s full-year profit plunged by more than two-thirds to $56 million
- Vodafone adding 34 European countries to ‘AU$5 per day’ international roaming option
- Telstra launches its new ‘Every Day Connect Data Share Packages’
- Voyager signs “multimillion-dollar deal” with submarine cable group Hawaiki